Abstracts tagged "Adenosine receptors and rheumatoid arthritis (RA)"

Abstract Number: 949 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study
Rumen M. Stoilov¹, Rodina N. Licheva², Mariyana K. Mihaylova³, Tatiana Reitblat⁴, Emil A. Dimitrov¹, Krasimira M. Shimbova¹, Girish Bhatia⁵, Amit Pispati⁶, Alexandra Gurman- Balbir⁷, B R Bagaria⁵, Boytcho A. Oparanov², Sari Fishman⁸, Zivit Harpaz⁸, Motti Farbstein⁸, Shira Cohen⁸, Michael H. Silverman⁸ and Pnina Fishman⁸, ¹Multiprofile Hospital for Active Treatment “Sv. Ivan Rilski” - EAD, Clinic of Rheumatology, Sofia, Bulgaria, ²Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, ³3Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, ⁴Barzilai Medical Center,, Ashkelon, Israel, ⁵Malpani Multispeciality Hospital, mumbai, India, ⁶Bhatia Hospital Medical Research Society, mumbai, India, ⁷Rambam Medical Center, Haifa, Israel, ⁸CanFite Biopharma Ltd, Petah Tikva, Israel
Background/Purpose: CF101, is a highly selective A3 adenosine receptor (A3AR) agonist, demonstrated safety and anti-inflammatory effect in Phase 2 clinical studies of rheumatoid arthritis (RA)…